{"product_id":"xeljanz-xr","title":"Xeljanz XR","description":"\u003ch3 data-start=\"268\" data-end=\"293\"\u003eWhat is Xeljanz XR?\u003c\/h3\u003e\r\n\u003cp data-start=\"294\" data-end=\"636\"\u003e\u003cstrong data-start=\"294\" data-end=\"308\"\u003eXeljanz XR\u003c\/strong\u003e is an extended‑release formulation of tofacitinib, an oral Janus kinase (JAK) inhibitor used for the treatment of moderately to severely active rheumatoid arthritis (RA). The XR formulation provides once‑daily dosing, offering improved convenience and potentially enhanced adherence compared with the immediate‑release version.\u003c\/p\u003e\r\n\u003cp data-start=\"638\" data-end=\"765\"\u003e\u003cem data-start=\"638\" data-end=\"765\"\u003eReference: U.S. Food and Drug Administration (FDA) Xeljanz XR Prescribing Information; ClinicalTrials.gov (e.g., NCT01039688)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"767\" data-end=\"770\"\u003e\r\n\u003ch3 data-start=\"772\" data-end=\"826\"\u003eWhat are the other popular names for Xeljanz XR?\u003c\/h3\u003e\r\n\u003cp data-start=\"827\" data-end=\"1104\"\u003eXeljanz XR is marketed under the brand name \u003cstrong data-start=\"871\" data-end=\"885\"\u003eXeljanz XR\u003c\/strong\u003e. It is also known by its generic name, \u003cstrong data-start=\"925\" data-end=\"957\"\u003etofacitinib extended‑release\u003c\/strong\u003e. In some clinical discussions, the immediate‑release version is simply called \u003cstrong data-start=\"1036\" data-end=\"1047\"\u003eXeljanz\u003c\/strong\u003e, while the extended‑release form is distinguished as XR.\u003c\/p\u003e\r\n\u003cp data-start=\"1106\" data-end=\"1140\"\u003e\u003cem data-start=\"1106\" data-end=\"1140\"\u003eReference: U.S. FDA; MedlinePlus\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1142\" data-end=\"1145\"\u003e\r\n\u003ch3 data-start=\"1147\" data-end=\"1199\"\u003eWhat is the drug classification of Xeljanz XR?\u003c\/h3\u003e\r\n\u003cp data-start=\"1200\" data-end=\"1416\"\u003eXeljanz XR is classified as an \u003cstrong data-start=\"1231\" data-end=\"1268\"\u003eoral Janus kinase (JAK) inhibitor\u003c\/strong\u003e. It belongs to the therapeutic class of immunomodulatory agents used in the management of autoimmune conditions—specifically, rheumatoid arthritis.\u003c\/p\u003e\r\n\u003cp data-start=\"1418\" data-end=\"1495\"\u003e\u003cem data-start=\"1418\" data-end=\"1495\"\u003eReference: U.S. FDA; National Institutes of Health (NIH) clinical resources\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"1497\" data-end=\"1500\"\u003e\r\n\u003ch3 data-start=\"1502\" data-end=\"1549\"\u003eWhat is the mode of action of Xeljanz XR?\u003c\/h3\u003e\r\n\u003cp data-start=\"1550\" data-end=\"1950\"\u003eXeljanz XR works by inhibiting key JAK enzymes (primarily JAK1 and JAK3) that are involved in the JAK‑STAT signaling pathway. This pathway plays a crucial role in mediating the inflammatory and immune responses seen in rheumatoid arthritis. By blocking JAK activity, Xeljanz XR reduces the production of pro‑inflammatory cytokines, thereby diminishing joint inflammation, pain, and progression of RA.\u003c\/p\u003e\r\n\u003cp data-start=\"1952\" data-end=\"2027\"\u003e\u003cem data-start=\"1952\" data-end=\"2027\"\u003eReference: PubMed (e.g., O’Shea et al., 2013 on JAK inhibitors); U.S. FDA\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2029\" data-end=\"2032\"\u003e\r\n\u003ch3 data-start=\"2034\" data-end=\"2080\"\u003eWhat are the primary uses of Xeljanz XR?\u003c\/h3\u003e\r\n\u003cp data-start=\"2081\" data-end=\"2418\"\u003eXeljanz XR is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response or intolerance to one or more disease‑modifying antirheumatic drugs (DMARDs). Its once‑daily dosing is designed to help control joint pain, swelling, and functional impairment associated with RA.\u003c\/p\u003e\r\n\u003cp data-start=\"2420\" data-end=\"2527\"\u003e\u003cem data-start=\"2420\" data-end=\"2527\"\u003eReference: U.S. FDA Xeljanz XR Prescribing Information; American College of Rheumatology (ACR) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"2529\" data-end=\"2532\"\u003e\r\n\u003ch3 data-start=\"2534\" data-end=\"2605\"\u003eWhat is the recommended dosage and administration for Xeljanz XR?\u003c\/h3\u003e\r\n\u003cul data-start=\"2606\" data-end=\"3034\"\u003e\r\n\u003cli data-start=\"2606\" data-end=\"2745\"\u003e\n\u003cstrong data-start=\"2608\" data-end=\"2619\"\u003eDosage:\u003c\/strong\u003e\r\n\u003cul data-start=\"2624\" data-end=\"2745\"\u003e\r\n\u003cli data-start=\"2624\" data-end=\"2745\"\u003eThe typical recommended dose for rheumatoid arthritis is \u003cstrong data-start=\"2683\" data-end=\"2703\"\u003e11 mg once daily\u003c\/strong\u003e using the extended‑release formulation.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"2746\" data-end=\"3034\"\u003e\n\u003cstrong data-start=\"2748\" data-end=\"2767\"\u003eAdministration:\u003c\/strong\u003e\r\n\u003cul data-start=\"2772\" data-end=\"3034\"\u003e\r\n\u003cli data-start=\"2772\" data-end=\"2887\"\u003eXeljanz XR is taken orally, with or without food, at the same time each day to maintain consistent drug levels.\u003c\/li\u003e\r\n\u003cli data-start=\"2890\" data-end=\"3034\"\u003eIt should be used exactly as prescribed by a healthcare provider, and patients should not alter the dosage without consulting their physician.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"3036\" data-end=\"3132\"\u003e\u003cem data-start=\"3036\" data-end=\"3132\"\u003eReference: U.S. FDA Xeljanz XR Prescribing Information; ClinicalTrials.gov (e.g., NCT01039688)\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"3134\" data-end=\"3137\"\u003e\r\n\u003ch3 data-start=\"3139\" data-end=\"3202\"\u003eWhat prescribing information is important for Xeljanz XR?\u003c\/h3\u003e\r\n\u003cul data-start=\"3203\" data-end=\"4001\"\u003e\r\n\u003cli data-start=\"3203\" data-end=\"3380\"\u003e\n\u003cstrong data-start=\"3205\" data-end=\"3221\"\u003eIndications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3226\" data-end=\"3380\"\u003e\r\n\u003cli data-start=\"3226\" data-end=\"3380\"\u003eXeljanz XR is approved for adults with moderately to severely active rheumatoid arthritis who have not responded adequately to conventional therapies.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3381\" data-end=\"3586\"\u003e\n\u003cstrong data-start=\"3383\" data-end=\"3405\"\u003eContraindications:\u003c\/strong\u003e\r\n\u003cul data-start=\"3410\" data-end=\"3586\"\u003e\r\n\u003cli data-start=\"3410\" data-end=\"3586\"\u003eIt is contraindicated in patients with active serious infections, known hypersensitivity to tofacitinib or its components, and those with certain hematologic abnormalities.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3587\" data-end=\"3815\"\u003e\n\u003cstrong data-start=\"3589\" data-end=\"3617\"\u003eMonitoring Requirements:\u003c\/strong\u003e\r\n\u003cul data-start=\"3622\" data-end=\"3815\"\u003e\r\n\u003cli data-start=\"3622\" data-end=\"3815\"\u003ePatients should be regularly monitored for signs of infection, complete blood counts, liver enzymes, and lipid profiles, as well as screened for latent tuberculosis before initiating therapy.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"3816\" data-end=\"4001\"\u003e\n\u003cstrong data-start=\"3818\" data-end=\"3845\"\u003eSpecial Considerations:\u003c\/strong\u003e\r\n\u003cul data-start=\"3850\" data-end=\"4001\"\u003e\r\n\u003cli data-start=\"3850\" data-end=\"4001\"\u003eXeljanz XR is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception during treatment.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"4003\" data-end=\"4112\"\u003e\u003cem data-start=\"4003\" data-end=\"4112\"\u003eReference: U.S. FDA; National Institutes of Health (NIH); American College of Rheumatology (ACR) guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"4114\" data-end=\"4117\"\u003e\r\n\u003ch3 data-start=\"4119\" data-end=\"4218\"\u003eWhat safety information, side effects, warnings, and cautions are associated with Xeljanz XR?\u003c\/h3\u003e\r\n\u003cul data-start=\"4219\" data-end=\"5175\"\u003e\r\n\u003cli data-start=\"4219\" data-end=\"4330\"\u003e\n\u003cstrong data-start=\"4221\" data-end=\"4245\"\u003eCommon Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4250\" data-end=\"4330\"\u003e\r\n\u003cli data-start=\"4250\" data-end=\"4330\"\u003eUpper respiratory tract infections, headache, diarrhea, and nasopharyngitis.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4331\" data-end=\"4500\"\u003e\n\u003cstrong data-start=\"4333\" data-end=\"4358\"\u003eSerious Side Effects:\u003c\/strong\u003e\r\n\u003cul data-start=\"4363\" data-end=\"4500\"\u003e\r\n\u003cli data-start=\"4363\" data-end=\"4500\"\u003eIncreased risk of serious infections (including tuberculosis), blood clots, and potential increases in cholesterol and liver enzymes.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"4501\" data-end=\"5175\"\u003e\n\u003cstrong data-start=\"4503\" data-end=\"4527\"\u003eWarnings \u0026amp; Cautions:\u003c\/strong\u003e\r\n\u003cul data-start=\"4532\" data-end=\"5175\"\u003e\r\n\u003cli data-start=\"4532\" data-end=\"4683\"\u003e\n\u003cstrong data-start=\"4534\" data-end=\"4549\"\u003eInfections:\u003c\/strong\u003e There is a heightened risk of opportunistic infections; patients should be monitored closely and educated about infection symptoms.\u003c\/li\u003e\r\n\u003cli data-start=\"4686\" data-end=\"4793\"\u003e\n\u003cstrong data-start=\"4688\" data-end=\"4714\"\u003eThromboembolic Events:\u003c\/strong\u003e An increased risk of venous thromboembolism has been noted in some patients.\u003c\/li\u003e\r\n\u003cli data-start=\"4796\" data-end=\"4908\"\u003e\n\u003cstrong data-start=\"4798\" data-end=\"4818\"\u003eMalignancy Risk:\u003c\/strong\u003e Long-term immunosuppression may increase the risk of certain cancers, such as lymphoma.\u003c\/li\u003e\r\n\u003cli data-start=\"4911\" data-end=\"5031\"\u003e\n\u003cstrong data-start=\"4913\" data-end=\"4932\"\u003eLiver Function:\u003c\/strong\u003e Regular monitoring of liver enzymes is recommended, as Xeljanz XR can cause hepatic abnormalities.\u003c\/li\u003e\r\n\u003cli data-start=\"5034\" data-end=\"5172\"\u003e\n\u003cstrong data-start=\"5036\" data-end=\"5050\"\u003ePregnancy:\u003c\/strong\u003e Xeljanz XR is contraindicated during pregnancy; effective contraception is mandatory for women of childbearing potential.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"5176\" data-end=\"5305\"\u003e\u003cem data-start=\"5176\" data-end=\"5305\"\u003eReference: U.S. FDA Xeljanz XR Prescribing Information; New England Journal of Medicine (NEJM) clinical studies; ACR guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"5307\" data-end=\"5310\"\u003e\r\n\u003ch3 data-start=\"5312\" data-end=\"5378\"\u003eWhat drug interactions should be considered with Xeljanz XR?\u003c\/h3\u003e\r\n\u003cul data-start=\"5379\" data-end=\"6047\"\u003e\r\n\u003cli data-start=\"5379\" data-end=\"5566\"\u003e\n\u003cstrong data-start=\"5381\" data-end=\"5403\"\u003eCYP3A4 Inhibitors:\u003c\/strong\u003e\r\n\u003cul data-start=\"5408\" data-end=\"5566\"\u003e\r\n\u003cli data-start=\"5408\" data-end=\"5566\"\u003eConcomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase tofacitinib levels, potentially enhancing adverse effects.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5567\" data-end=\"5731\"\u003e\n\u003cstrong data-start=\"5569\" data-end=\"5598\"\u003eOther Immunosuppressants:\u003c\/strong\u003e\r\n\u003cul data-start=\"5603\" data-end=\"5731\"\u003e\r\n\u003cli data-start=\"5603\" data-end=\"5731\"\u003eUse with other potent immunosuppressive agents may increase the risk of serious infections; careful monitoring is essential.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5732\" data-end=\"5862\"\u003e\n\u003cstrong data-start=\"5734\" data-end=\"5747\"\u003eVaccines:\u003c\/strong\u003e\r\n\u003cul data-start=\"5752\" data-end=\"5862\"\u003e\r\n\u003cli data-start=\"5752\" data-end=\"5862\"\u003eLive vaccines should generally be avoided during treatment with Xeljanz XR due to immunosuppressive effects.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003cli data-start=\"5863\" data-end=\"6047\"\u003e\n\u003cstrong data-start=\"5865\" data-end=\"5887\"\u003eOther Medications:\u003c\/strong\u003e\r\n\u003cul data-start=\"5892\" data-end=\"6047\"\u003e\r\n\u003cli data-start=\"5892\" data-end=\"6047\"\u003eAlways inform your healthcare provider of all concomitant medications, including over-the-counter drugs and supplements, to avoid potential interactions.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"6049\" data-end=\"6127\"\u003e\u003cem data-start=\"6049\" data-end=\"6127\"\u003eReference: U.S. FDA; Clinical Pharmacology Reviews on PubMed; NIH guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"6129\" data-end=\"6132\"\u003e\r\n\u003ch3 data-start=\"6134\" data-end=\"6173\"\u003eFrequently Asked Questions (FAQs)\u003c\/h3\u003e\r\n\u003cp data-start=\"6175\" data-end=\"6484\"\u003e\u003cstrong data-start=\"6175\" data-end=\"6240\"\u003eQ: How does Xeljanz XR differ from immediate-release Xeljanz?\u003c\/strong\u003e\u003cbr data-start=\"6240\" data-end=\"6243\"\u003eA: Xeljanz XR provides once‑daily dosing (11 mg once daily) compared to immediate‑release Xeljanz, which is typically dosed at 5 mg twice daily. This extended‑release formulation offers improved convenience and may enhance patient adherence.\u003c\/p\u003e\r\n\u003cp data-start=\"6486\" data-end=\"6709\"\u003e\u003cstrong data-start=\"6486\" data-end=\"6553\"\u003eQ: How quickly can I expect to see improvements in my symptoms?\u003c\/strong\u003e\u003cbr data-start=\"6553\" data-end=\"6556\"\u003eA: Some patients report improvement in joint pain and swelling within 2–4 weeks; however, maximum therapeutic benefits may take longer to become evident.\u003c\/p\u003e\r\n\u003cp data-start=\"6711\" data-end=\"7000\"\u003e\u003cstrong data-start=\"6711\" data-end=\"6770\"\u003eQ: What precautions should I take regarding infections?\u003c\/strong\u003e\u003cbr data-start=\"6770\" data-end=\"6773\"\u003eA: Due to an increased risk of serious infections, patients should be screened for latent tuberculosis and monitored regularly for signs of infection. Report any symptoms such as fever, cough, or persistent malaise immediately.\u003c\/p\u003e\r\n\u003cp data-start=\"7002\" data-end=\"7226\"\u003e\u003cstrong data-start=\"7002\" data-end=\"7047\"\u003eQ: Can Xeljanz XR be used as monotherapy?\u003c\/strong\u003e\u003cbr data-start=\"7047\" data-end=\"7050\"\u003eA: Xeljanz XR may be used as monotherapy or in combination with methotrexate in patients with rheumatoid arthritis, depending on the clinical scenario and treatment guidelines.\u003c\/p\u003e\r\n\u003cp data-start=\"7228\" data-end=\"7458\"\u003e\u003cstrong data-start=\"7228\" data-end=\"7271\"\u003eQ: Is Xeljanz XR safe during pregnancy?\u003c\/strong\u003e\u003cbr data-start=\"7271\" data-end=\"7274\"\u003eA: Xeljanz XR is contraindicated during pregnancy. Women of childbearing potential should use effective contraception during treatment and for a specified period after discontinuation.\u003c\/p\u003e\r\n\u003cp data-start=\"7460\" data-end=\"7532\"\u003e\u003cem data-start=\"7460\" data-end=\"7532\"\u003eReference: U.S. FDA Xeljanz XR Prescribing Information; ACR guidelines\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"7534\" data-end=\"7537\"\u003e\r\n\u003ch3 data-start=\"7539\" data-end=\"7633\"\u003eWhere can I find additional clinical evidence and detailed information about Xeljanz XR?\u003c\/h3\u003e\r\n\u003cp data-start=\"7634\" data-end=\"7720\"\u003eFor more in-depth clinical data, dosing guidelines, and safety monitoring, refer to:\u003c\/p\u003e\r\n\u003cul data-start=\"7721\" data-end=\"8043\"\u003e\r\n\u003cli data-start=\"7721\" data-end=\"7809\"\u003e\n\u003cstrong data-start=\"7723\" data-end=\"7775\"\u003eU.S. Food and Drug Administration (FDA) Website:\u003c\/strong\u003e \u003ca href=\"https:\/\/www.fda.gov\/\" target=\"_new\" rel=\"noopener\" data-start=\"7776\" data-end=\"7807\"\u003eFDA.gov\u003c\/a\u003e\n\u003c\/li\u003e\r\n\u003cli data-start=\"7810\" data-end=\"7872\"\u003e\n\u003cstrong data-start=\"7812\" data-end=\"7835\"\u003eClinicalTrials.gov:\u003c\/strong\u003e (e.g., NCT01039688 for RA studies)\u003c\/li\u003e\r\n\u003cli data-start=\"7873\" data-end=\"7945\"\u003e\n\u003cstrong data-start=\"7875\" data-end=\"7886\"\u003ePubMed:\u003c\/strong\u003e For peer‑reviewed articles on tofacitinib and Xeljanz XR\u003c\/li\u003e\r\n\u003cli data-start=\"7946\" data-end=\"8043\"\u003e\u003cstrong data-start=\"7948\" data-end=\"8041\"\u003eAmerican College of Rheumatology (ACR) and National Institutes of Health (NIH) guidelines\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-start=\"8045\" data-end=\"8105\"\u003e\u003cem data-start=\"8045\" data-end=\"8105\"\u003eReference: U.S. FDA; ClinicalTrials.gov; NEJM; PubMed; ACR\u003c\/em\u003e\u003c\/p\u003e\r\n\u003chr data-start=\"8107\" data-end=\"8110\"\u003e\r\n\u003ch3 data-start=\"8112\" data-end=\"8132\"\u003eFinal Thoughts\u003c\/h3\u003e\r\n\u003cp data-start=\"8133\" data-end=\"8759\"\u003e\u003cstrong data-start=\"8133\" data-end=\"8164\"\u003eXeljanz XR (tofacitinib XR)\u003c\/strong\u003e is an effective oral JAK inhibitor designed to manage rheumatoid arthritis by reducing inflammation through inhibition of the JAK‑STAT pathway. With its convenient once‑daily dosing, Xeljanz XR offers an attractive option for patients seeking to improve their symptoms and quality of life. However, due to the potential for serious adverse effects, including infections and thromboembolic events, careful patient selection, monitoring, and management of drug interactions are essential. Always consult your healthcare provider to ensure Xeljanz XR is the appropriate therapy for your condition.\u003c\/p\u003e\r\n\u003cp data-start=\"8761\" data-end=\"8979\"\u003e\u003cem data-start=\"8761\" data-end=\"8979\"\u003eDisclaimer: This guide is intended for educational purposes only and should not replace professional medical advice. Always consult with your healthcare provider before initiating or modifying any medication regimen.\u003c\/em\u003e\u003c\/p\u003e","brand":"EZ Chemist","offers":[{"title":"11mg","offer_id":51735708631323,"sku":"Generic Xeljanz XR (Tofacitinib Extended Release) 11mg-1","price":81.6,"currency_code":"USD","in_stock":true}],"url":"https:\/\/ezchemist.com\/products\/xeljanz-xr","provider":"EZ Chemist","version":"1.0","type":"link"}